FDA-hysbakke hou die uniQure-program vir genterapie vir hemofilie B in

FDA-hysbakke hou die uniQure-program vir genterapie vir hemofilie B in
Image

Please enable the javascript to submit this form

Ondersteun deur opvoedkundige toekennings van Bayer, BioMarin, CSL Behring, Freeline Therapeutics Limited, Pfizer Inc., Spark Therapeutics en uniQure, Inc.

Noodsaaklike SSL